Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 599

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Filgrastim (r-metHuG-CSF): the first 10 years

Open access
Welte, K, Gabrilove, J, Bronchud, MH, Platzer, E, Morstyn, G · 1996 · Blood

Abstract

T HAS BEEN KNOWN for at least three decades that very specific factors control hematopoiesis, acting on early cells in the hematopoietic system to produce mature, functional cells. The isolation, purification, and cloning of these factors has lead to a new class of therapeutic agents, including the colony-stimulating factors and interleukins. This review is devoted to granulocyte colony-stimulating factor (G-CSF), specifically Filgrastim (r-metHuG-CSF), the bacterially synthesized recombinant protein form of GCSF, that acts on neutrophils, the body's major defense against infections. The purification and molecular cloning of Filgrastim were performed between 1984 and 1986,L-3 and the clinical development of Filgrastim commenced in 1986, with approval for clinical use in cancer patients treated with chemotherapy4 obtained in the United States in February 1991. In the 5 years since its approval, 1.2 million patients have been treated with Filgrastim (Amgen [Thousand Oaks, CA], data on file). Filgrastim was initially used as an adjunct to chemotherapy for ameliorating neutropenia, one of the major side effects of cancer chemotherapy. Its use has led to reduced infections and hospital admissions for patients with cancer. Besides chemotherapy-induced neutropenia, Filgrastim has been approved in more than 70 countries for the treatment of myelosuppression after bone marrow transplantation, severe chronic neutropenia (SCN), acute leukemia, aplastic anemia (AA), myelodysplastic syndromes (MDS), and mobilization of peripheral blood progenitor cells (PBPCs) for transplantation. The use of Filgrastim has made possible delivery of full-dose chemotherapy and high-dose chemotherapy and has benefited patients who are immunocompromised. A second form of rHuG-CSF (lenograstim) received approval in Europe in 1993. The biologic properties of Filgrastim and lenograstim are similar and are given in Table 1. This review focuses on Filgrastim and reviews the first 10 years of clinical development and the first 5 years of postapproval use as well as additional potential clinical applications. PHARMACOLOGY OF FlLGRASTlM The pharmacodynamics and pharmacokinetics of Filgrastim were studied in rodents',' and primates. and then in normal volunteers and in patients with malignant disease. The results of these studies indicated that Filgrastim had a consistent and predictable pharmacologic profile when ad

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v88.6.1907.bloodjournal8861907

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 64 references

Metadata

Authors
Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G.
Venue
Blood
Published
1996-09-15
Volume
88
Issue
6
Pages
1907-1929
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W202042235
Cited by
599
References
64
FWCI
10.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Filgrastim (r-metHuG-CSF): the first 10 years. https://app.cochat.ai/papers/10.1182/blood.v88.6.1907.bloodjournal8861907
The paper
Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G. (1996). Filgrastim (r-metHuG-CSF): the first 10 years. Blood. https://doi.org/10.1182/blood.v88.6.1907.bloodjournal8861907

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.